Qinecsa ICSR Management logo

Qinecsa ICSR Management

by Qinecsaqinecsa.com
VISIT OFFICIAL WEBSITE →

OVERVIEW

End-to-end pharmacovigilance solution for Individual Case Safety Report (ICSR) management, leveraging a unified, scalable SaaS platform for intake, processing, and regulatory submission.

Qinecsa ICSR Management offers comprehensive, end-to-end services and technology for handling Individual Case Safety Reports (ICSRs), forming the cornerstone of a robust pharmacovigilance (PV) system. The solution is designed to simplify and enhance PV processes, ensuring the highest level of safety and global regulatory compliance.

The core of the technology is the Reportum Platform, a unified adverse event platform that manages both digital and analogue initial and follow-up reports across global sources and languages. It provides a digital-first experience for consumers and healthcare professionals, as well as expert pharma users in call centers and other organizations. The platform automates the ingestion of standard PV forms like CIOMS and MedWatch and offers a centralized solution for both legacy and digital workflows.

Key Capabilities:

  • Intake & Triage: Systematic collection of adverse events from multiple channels (spontaneous, literature, digital platforms) with automated triage to determine urgency and seriousness.
  • Case Processing: Comprehensive services covering data entry, quality review, medical review by qualified professionals, and narrative development.
  • Automation & Efficiency: Leverages state-of-the-art safety database systems and automation tools to streamline workflows, reduce manual effort, and accelerate turnaround times.
  • Regulatory Submission: Ensures seamless and timely ICSR submissions worldwide, supporting automated E2BR2/R3 transfer into the safety database and maintaining current knowledge of region-specific formats and timelines.
  • Data Migration: Provides secure, optimized data migration services for transferring ICSR data from one safety database to another while preserving data integrity and audit trails.
  • Literature Screening: Utilizes advanced technology, including AI, to merge expertise with automation for comprehensive global and local literature screening and review, identifying ICSRs and potential safety signals.

Qinecsa's solution is a fully verified and highly scalable SaaS platform, offering flexibility to work within a client's existing safety database infrastructure or provide access to their own validated systems. It is targeted at pharmaceutical companies, CROs, and life sciences organizations seeking to manage fluctuating case volumes and maintain compliance without the overhead of building an in-house team.

RATING & STATS

Founded
2006

KEY FEATURES

  • End-to-End ICSR Case Processing
  • Unified Digital/Analogue Adverse Event Intake (Reportum)
  • Automated E2BR2/R3 Regulatory Transfer
  • AI-Powered Literature Screening and Translation
  • Configurable Forms and Workflows (PV Design Studio)
  • Global Regulatory Submission and Tracking
  • Expert Medical Review and Causality Assessment
  • Data Migration Services

PRICING

Model: enterprise
Pricing is not publicly disclosed and is based on enterprise-level engagement, likely following a custom subscription model based on case volume and service requirements.

TECHNICAL DETAILS

Deployment: saas, cloud
Platforms: web, ios, android
🔌 API Available

USE CASES

Individual Case Safety Report (ICSR) ProcessingRegulatory Compliance and SubmissionPharmacovigilance Case Intake and TriageDrug Safety Data Migration

INTEGRATIONS

Safety Database Systems (via E2B transfer)Downstream Systems

COMPLIANCE & SECURITY

Compliance:
EudravigilanceFDA 21 CFR Part 11GDPR
Security Features:
  • 🔒High Availability Cloud Infrastructure
  • 🔒Data Privacy Adherence

SUPPORT & IMPLEMENTATION

Support: email, phone, dedicated account manager
Implementation Time: 1-3 months
Target Company Size: medium, enterprise
TRAINING AVAILABLE

PROS & CONS

✓ Pros:
  • +Unified platform for digital and analogue adverse event intake.
  • +Scalable SaaS solution suitable for fluctuating case volumes.
  • +Deep regulatory expertise ensuring global compliance (e.g., Eudravigilance).
  • +Leverages AI for efficiency (e.g., literature screening, translation).
  • +Flexible deployment (use own or Qinecsa's validated safety database).
✗ Cons:
  • -Pricing is not transparent and requires direct contact.
  • -Primarily marketed as a technology-enabled service, which may require outsourcing PV staff.
  • -No public reviews or ratings available for independent validation.

ABOUT QINECSA